Fresenius Medical Care AG & Co. KGaA (FMS) Stock: Price, Forecast & Analyst Target
Fresenius Medical Care AG & Co. KGaA (FMS) — MoonshotScore 83/100 (Exceptional band), calculated Oct 5, 2026. Price $22.25 (-0.02%), as of the Oct 2, 2026 trading session; market cap $12.0B. Expected results Nov 3, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Fresenius Medical Care AG & Co. KGaA · FMS · NYSE · Healthcare · Medical - Care Facilities
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Fresenius Medical Care AG & Co. KGaA (FMS)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, at a dirt-cheap price, but a strained balance sheet. Business Quality: Solid; Financial Safety: Strained; Valuation: Cheap; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $5.44B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 7 of 8
- Altman Z 1.74 · Piotroski F 8
Helping: business quality, an attractive price, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 81 | Exceptional | |
| 82 | Exceptional | |
| 83 | Exceptional | |
| 83 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional |
The score moved from 84 in the stored Oct 4, 2026 snapshot to 83 in the current publication computed Oct 5, 2026 (-1); the largest pillar moves were Growth Durability -4. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $22.25 | |
| Change on the day | -0.02% | |
| 52-week range | $20.02 – $27.64 | |
| Market capitalisation | $12.0B | |
| Price / earnings (trailing) | 11.91 | |
| Shares traded on the day | 478.5K | |
| Beta (volatility vs the S&P 500) | 0.72 | |
| Dividends per share (last 12 months) | $0.86 | |
| Dividend yield (last 12 months) | 3.88% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Accordingly, we expect operating income to remain at a consistently elevated level in 2026 with an upside, downside range of a mid-single-digit percentage change.
Helen Giza · Statement from
Overall, we expect to deliver Care Enablement margin improvement in the second half and full year 2026 as we continue to execute our Reignite strategy while offsetting increased inflationary pressure from the Middle East conflict in our Care Enablement business.
Helen Giza · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Fresenius Medical Care AG & Co. KGaA (FMS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the FMS film — every key number, told as a short cinematic story
~2 min · open the film
What is Fresenius Medical Care AG & Co. KGaA (FMS), and what does it report?
Short answer · as of
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Fresenius Medical Care AG & Co. KGaA (FMS) is listed on NYSE. Healthcare / Medical Care Facilities SEC filing business address: Else-Kroener Strasse 1, BAD Homburg, 2M, 61352. It employs 108,165 people and is led by Helen Giza. In Q2 FY2026 it reported revenue of $5.44B and net income of $244M. The market values it at $12.0B.
What do the latest results show for Fresenius Medical Care AG & Co. KGaA (FMS)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $5.44B. Against analyst estimates the company has EPS beat 7 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $5.60B Aug 3, 2026
- Latest report · revenue estimate
- $5.48B Aug 3, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 3, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 3, 2026 | $5.60B | $5.48B | $0.6600 | $0.6160 |
| May 5, 2026 | $5.40B | $5.41B | $0.5300 | $0.5900 |
| Feb 24, 2026 | $5.97B | $5.67B | $0.8300 | $0.6470 |
| Nov 4, 2025 | $5.72B | $4.80B | $0.6400 | $0.5900 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $5.44B | $244M | $0.45 (diluted) |
| Q1 FY2026 | $5.16B | $131M | $0.24 (diluted) |
| Q4 FY2025 | $5.67B | $366M | $0.64 (diluted) |
| Q3 FY2025 | $5.46B | $307M | $0.53 (diluted) |
What are the financial strengths and risks for Fresenius Medical Care AG & Co. KGaA (FMS)?
Short answer
The MoonshotScore pillars rate business quality, an attractive price, durable growth as strengths. The distress and quality screens read Altman Z 1.74 · Piotroski F 8. Trailing ratios: ROE 7.2% · ROA 3.0% · current ratio 1.20 · earnings yield 8.7% · free-cash-flow yield 16.8%.
What should you watch next at Fresenius Medical Care AG & Co. KGaA (FMS)?
Short answer · as of
The next earnings report is expected on Nov 3, 2026. Current published price targets run low $19.90 · high $25.80 · consensus $23.67 · median $24.50 against a quoted price of $22.25 (as of Oct 2, 2026).
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Accordingly, we expect operating income to remain at a consistently elevated level in 2026 with an upside, downside range of a mid-single-digit percentage change.
Helen Giza ·
Overall, we expect to deliver Care Enablement margin improvement in the second half and full year 2026 as we continue to execute our Reignite strategy while offsetting increased inflationary pressure from the Middle East conflict in our Care Enablement business.
Helen Giza ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Fresenius Medical Care AG & Co. KGaA compare with its peers?
Short answer
Fresenius Medical Care AG & Co. KGaA's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $227.66 Oct 2, 2026 | $3.56B | 98 5-pillar Oct 5, 2026 | |
| $175.72 Oct 2, 2026 | $10.6B | 94 5-pillar Oct 5, 2026 | |
| $11.83 Oct 2, 2026 | $4.59B | 93 5-pillar Oct 5, 2026 | |
| $119.80 Oct 2, 2026 | $11.9B | 90 5-pillar Oct 5, 2026 | |
| $258.62 Oct 2, 2026 | $20.8B | 89 5-pillar Oct 5, 2026 | |
| $507.50 Oct 2, 2026 | $6.63B | 87 5-pillar Oct 5, 2026 | |
| Fresenius Medical Care AG & Co. KGaA (FMS) — this page | $22.25 | $12.0B | 83 |
| $22.64 Oct 2, 2026 | $3.39B | 81 5-pillar Oct 5, 2026 | |
| $12.59 Oct 2, 2026 | $2.74B | 81 5-pillar Oct 5, 2026 | |
| $178.69 Oct 2, 2026 | $11.5B | 75 5-pillar Oct 5, 2026 | |
| $171.78 Oct 2, 2026 | $10.0B | 75 5-pillar Oct 5, 2026 | |
| $57.16 Oct 2, 2026 | $25.3B | 73 5-pillar Oct 5, 2026 | |
| $87.85 Oct 2, 2026 | $15.2B | 61 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $19.90 – $25.80
- Consensus target
- $23.67
- Median target
- $24.50
Consensus record · Captured .
Measured against a quoted price of $22.25 (as of Oct 2, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 7.7% Period end Jun 30, 2026
- Previous quarter · ownership
- 7.7% Prior to period end Jun 30, 2026
- Reporting holders
- 242 Period end Jun 30, 2026
- Previous quarter · holders
- 224 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Pzena Investment Management LLC | 14,992,081 |
| Morgan Stanley | 4,347,748 |
| Dodge & Cox | 3,826,910 |
| Fiduciary Management INC /Wi/ | 2,937,829 |
| Brandes Investment Partners, LP | 1,916,090 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Fresenius Medical Care AG & Co. KGaA (FMS)?
FMS Healthcare Stock FAQ
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
What does Care Enablement contribute to Fresenius Medical Care?
Care Enablement supplies dialysis machines, dialyzers, solutions, bloodlines, medicines and related systems to treatment providers. Management is using Reignite to pursue margin improvement in this business while absorbing inflationary pressure linked to the Middle East conflict.
How does home dialysis fit into Fresenius Medical Care’s model?
Home dialysis extends the company beyond clinic-based treatment: Fresenius Medical Care provides equipment, patient training, clinical oversight, ongoing assistance and coordinated supply deliveries. Demand therefore includes continued support and consumables as well as the initial equipment placement.
What is the FMS stock price today?
The last price recorded on this page for Fresenius Medical Care AG & Co. KGaA (FMS) is $22.25, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the FMS price target?
The analyst consensus price target for Fresenius Medical Care AG & Co. KGaA (FMS) is $23.67 (range $19.90 to $25.80, median $24.50), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does FMS pay a dividend?
Yes. Fresenius Medical Care AG & Co. KGaA (FMS) shows a trailing 12-month dividend yield of 3.88%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (57 figures)
The 57 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Helen Giza (Aug 4, 2026): Accordingly, we expect operating income to remain at a consistently elevated level in 2026 with an upside, downside range of a mid-single-digit percentage change. Helen Giza (Aug 4, 2026): Overall, we expect to deliver Care Enablement margin improvement in the second half and full year 2026 as we continue to execute our Reignite strategy while offsetting increased inflationary pressure from the Middle East conflict in our Care Enablement business. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Else-Kroener Strasse 1, BAD Homburg, 2M, 61352 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Else-KrOener Strasse 1, Bad Homburg, HE, 61352, DE". |
FMP — 44 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $22.25 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T00:34:47.109Z. | |
px.change | Change on the day | -0.02% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $12.0B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:03.000Z. Captured from FMP at 2026-10-05T00:34:46.132Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 3, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.005 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $5.44B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 11.91 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 478.5K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.72 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Care Facilities | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 8090 — Services-Misc Health & Allied Services, NEC. | |
id.employees | Employees | 108,165 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
id.ceo | Chief executive | Helen Giza | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_income | Net income, Q2 FY2026 | $244M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-03.revenue_actual | Revenue · reported — report date 2026-08-03 | $5.60B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.revenue_estimated | Revenue · estimate — report date 2026-08-03 | $5.48B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.eps_actual | EPS · reported — report date 2026-08-03 | $0.6600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-03.eps_estimated | EPS · estimate — report date 2026-08-03 | $0.6160 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_actual | Revenue · reported — report date 2026-05-05 | $5.40B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_estimated | Revenue · estimate — report date 2026-05-05 | $5.41B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_actual | EPS · reported — report date 2026-05-05 | $0.5300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_estimated | EPS · estimate — report date 2026-05-05 | $0.5900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.revenue_actual | Revenue · reported — report date 2026-02-24 | $5.97B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.revenue_estimated | Revenue · estimate — report date 2026-02-24 | $5.67B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.eps_actual | EPS · reported — report date 2026-02-24 | $0.8300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.eps_estimated | EPS · estimate — report date 2026-02-24 | $0.6470 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_actual | Revenue · reported — report date 2025-11-04 | $5.72B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_estimated | Revenue · estimate — report date 2025-11-04 | $4.80B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_actual | EPS · reported — report date 2025-11-04 | $0.6400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_estimated | EPS · estimate — report date 2025-11-04 | $0.5900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $19.90 · high $25.80 · consensus $23.67 · median $24.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $19.90 – $25.80 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $23.67 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $24.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.institutions.depth.ownership_pct | Institutional ownership | 7.7% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 7.7% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 242 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 224 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Pzena Investment Management LLC — shares in provider snapshot | 14,992,081 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Morgan Stanley — shares in provider snapshot | 4,347,748 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Dodge & Cox — shares in provider snapshot | 3,826,910 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Fiduciary Management INC /Wi/ — shares in provider snapshot | 2,937,829 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Brandes Investment Partners, LP — shares in provider snapshot | 1,916,090 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 7 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-03 | |
fin.scores | Distress and quality screens | Altman Z 1.74 · Piotroski F 8 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
px.range52 | 52-week range | $20.02 – $27.64 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 7.2% · ROA 3.0% · current ratio 1.20 · earnings yield 8.7% · free-cash-flow yield 16.8% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.86 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 3.88% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-03.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($5.60B) with the recorded estimate ($5.48B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-03.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.6600) with the recorded estimate ($0.6160) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 83 of 100 · Exceptional · pillars 78 / 39 / 94 / 81 / 62 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 84 (stored snapshot Oct 4, 2026) → 83 (current publication computed Oct 5, 2026) (-1) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. | |
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-03. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-03.revenue_actual,earn.history.depth.2026-08-03.revenue_estimated,earn.history.depth.2026-08-03.revenue_actual.comparison,earn.history.depth.2026-08-03.eps_actual.comparison,earn.history.depth.2026-08-03.eps_actual,earn.history.depth.2026-08-03.eps_estimated,earn.history.depth.2026-05-05.revenue_actual,earn.history.depth.2026-05-05.revenue_estimated,earn.history.depth.2026-05-05.eps_actual,earn.history.depth.2026-05-05.eps_estimated,earn.history.depth.2026-02-24.revenue_actual,earn.history.depth.2026-02-24.revenue_estimated,earn.history.depth.2026-02-24.eps_actual,earn.history.depth.2026-02-24.eps_estimated,earn.history.depth.2025-11-04.revenue_actual,earn.history.depth.2025-11-04.revenue_estimated,earn.history.depth.2025-11-04.eps_actual,earn.history.depth.2025-11-04.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Management outlook — dated call excerpts | Captured record · 2 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-04 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
Data provided for informational purposes only.